Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Uber Stock (UBER) Slides on FTC Uber One Lawsuit as Analysts Hold Bullish Targets — What to Know on Dec. 16, 2025

Uber Stock (UBER) Slides on FTC Uber One Lawsuit as Analysts Hold Bullish Targets — What to Know on Dec. 16, 2025

Uber Technologies, Inc. (NYSE: UBER) stock traded lower on Tuesday, December 16, 2025, as investors digested an escalated regulatory challenge tied to the company’s Uber One subscription program—while Wall Street’s broader outlook on the rideshare and delivery leader stayed notably constructive. As of 11:22 UTC on Dec. 16, Uber shares were at $81.86, down about 3.84% from the prior close. The day’s move highlights a familiar pattern for Uber stock: near-term volatility driven by legal and regulatory headlines, set against a longer-running debate about whether Uber’s platform strategy—spanning Mobility, Delivery, and an expanding set of partnerships—can compound profitably into 2026
16 December 2025
·
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a steady drumbeat of pipeline and regulatory updates heading into 2026. Smartkarma While BMY has spent much of the past year wrestling with familiar big-pharma headwinds—generic erosion in legacy products and a looming “patent cliff” narrative—the last several weeks have looked more like a sentiment reset than a victory lap. One analysis notes a ~16% move over the last 30 days
16 December 2025
···
Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is still living inside one of the more dramatic biotech story arcs of 2025: eye-popping clinical data, followed immediately by a massive equity raise, followed by a flurry of analyst price-target resets. As of Tuesday, December 16, 2025, TERN shares were trading around $44. That price level matters because it sits right on top of the two big forces investors have been digesting all month: Below is a complete, publication-ready roundup of the current news, forecasts, and market analysis shaping Terns Pharmaceuticals stock as of 16.12.2025, plus the catalysts that could drive the next move.
16 December 2025
··
Venus Concept Inc. (NASDAQ: VERO) Stock: Latest News, Catalysts, and Forecasts as of December 16, 2025

Venus Concept Inc. (NASDAQ: VERO) Stock: Latest News, Catalysts, and Forecasts as of December 16, 2025

Venus Concept Inc. stock (NASDAQ: VERO) is back on traders’ radar in mid-December 2025—less because it’s a calm, steadily compounding story (it isn’t), and more because the company has stacked multiple high-impact catalysts and balance-sheet developments into a tight window. As of the Dec. 15 close, VERO finished around $1.67, down roughly 10.7% on the day, and early Dec. 16 pre-market quotes indicated a sharp rebound attempt near $2.16—a reminder that this remains a thinly traded micro-cap where price can gap hard in either direction. StockAnalysis Below is a full, publication-ready breakdown of the latest company news, what recent filings
16 December 2025
·
Inspire Veterinary Partners (IVP) Stock News Today: Nasdaq Delisting Risk, Dilution Signals, and 2026 Catalysts (Dec. 16, 2025)

Inspire Veterinary Partners (IVP) Stock News Today: Nasdaq Delisting Risk, Dilution Signals, and 2026 Catalysts (Dec. 16, 2025)

December 16, 2025 — Inspire Veterinary Partners, Inc. (NASDAQ: IVP) is once again on traders’ radar, but not for the comforting reasons investors typically like in a healthcare-services name. The stock is trading around $0.05 per share in early Tuesday action, after a stretch of extreme volatility driven by Nasdaq listing risk, capital-structure changes, and a growing conversation around potential dilution. Investing.com Below is a complete, up-to-date rundown of the latest IVP stock news, filings, forecasts, and analysis as of December 16, 2025, plus what to watch next. IVP stock price action on December 16, 2025: microcap volatility on full
16 December 2025
·
Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Inc. (NYSE: PFE) heads into Tuesday, December 16, 2025 with a familiar “big pharma” cocktail of catalysts: an imminent guidance event, a high dividend yield, fresh dealmaking in hot therapeutic areas (immunology and obesity), and a regulatory backdrop that can flip sentiment faster than a lab centrifuge. Shares closed Monday at $26.43, up 2.24%, extending a four-session winning streak, according to MarketWatch. MarketWatch On the data side, Pfizer’s own calendar is the center of gravity: the company is scheduled to host an 8:00 a.m. EST analyst call today to provide full-year 2026 financial guidance. Pfizer+1 Below is what’s driving
16 December 2025
···
Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Nektar Therapeutics (NASDAQ: NKTR) is in classic “biotech catalyst mode” on December 16, 2025—the kind of day when a single dataset can rewrite a stock chart in minutes. Shares climbed in pre-market and overnight trading as investors positioned for topline results from the 36-week induction period of Nektar’s Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata, featuring its lead investigational candidate rezpegaldesleukin (REZPEG / NKTR-358). The company scheduled an investor call and webcast for 8:00 a.m. ET, and said the topline results would be released in a morning press release before the webcast. PR Newswire+1 By the numbers, NKTR closed
16 December 2025
··
SAVE Plan Shutdown: Student Loan Payments Could Restart for Millions—What Borrowers Need to Know (Dec. 16, 2025)

SAVE Plan Shutdown: Student Loan Payments Could Restart for Millions—What Borrowers Need to Know (Dec. 16, 2025)

Dec. 16, 2025 — Millions of Americans enrolled in the Biden-era Saving on a Valuable Education (SAVE) student loan repayment plan are facing a major—and fast-moving—shift that could end a long stretch of ultra-low or even $0 monthly bills. The U.S. Department of Education says it has reached a proposed settlement with Missouri that would end the SAVE plan, halt new enrollments, deny pending applications, and move current SAVE borrowers into other repayment options—pending court approval. U.S. Department of Education+1 For borrowers, the immediate reality is a mix of urgency and uncertainty: the department says SAVE enrollees will have a
16 December 2025
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

Dec. 16, 2025 — uniQure N.V. (NASDAQ: QURE) is back in the spotlight Tuesday after a notable extended-hours rebound. The gene therapy developer’s shares were highlighted among top pre-market gainers, rising about 15% to roughly $23.50 in early trading, following a strong after-hours move the prior session. StockAnalysis+1 The snapback comes at a time when the fundamental narrative around uniQure remains dominated by one big question: how (and when) the U.S. FDA will allow AMT-130—uniQure’s Huntington’s disease gene therapy—to move toward a Biologics License Application (BLA) after the agency signaled the current evidence package is not sufficient as “primary” support
16 December 2025
··
Procter & Gamble Stock (PG) News Today: Price Rally Extends, Leadership Shifts, Dividend Outlook and Analyst Forecasts (December 16, 2025)

Procter & Gamble Stock (PG) News Today: Price Rally Extends, Leadership Shifts, Dividend Outlook and Analyst Forecasts (December 16, 2025)

December 16, 2025 — The Procter & Gamble Company (NYSE: PG) is back in the market’s good graces after a choppy year for consumer staples. PG shares finished the latest session up 1.60% at $145.13, extending the stock’s winning streak to five straight days even as the broader market slipped. marketwatch.com That near-term momentum is colliding with a very “P&G” mix of catalysts: executive turnover, an approaching CEO handoff, and investor focus on dividends and pricing power. Here’s what’s driving Procter & Gamble stock today, what Wall Street is forecasting, and what to watch next as 2026 begins to loom
16 December 2025
··
Affirm Holdings (AFRM) Stock News Today: CFO Fireside Chat, Analyst Targets, and BNPL Scrutiny in Focus (Dec. 16, 2025)

Affirm Holdings (AFRM) Stock News Today: CFO Fireside Chat, Analyst Targets, and BNPL Scrutiny in Focus (Dec. 16, 2025)

December 16, 2025 — Affirm Holdings, Inc. (NASDAQ: AFRM) heads into today with investors watching two forces that can move buy-now-pay-later (BNPL) stocks fast: company messaging and policy risk. Shares closed Monday, Dec. 15 at $65.66, down 2.36% on the day, setting the stage for today’s investor-focused event featuring the company’s CFO. StockAnalysis That event—an interactive CFO fireside chat scheduled for 9:00 a.m. Pacific—is the most immediate near-term catalyst for AFRM on the calendar, arriving after a newsy December that’s mixed product/merchant momentum with rising attention on BNPL oversight. Business Wire What’s happening today: Affirm’s CFO fireside chat (and why
16 December 2025
·
Singapore Bank Stocks Hit Record Highs on Dec 16, 2025: DBS and OCBC Surge, UOB Lags as Investors Eye Dividends and 2026 Momentum

Singapore Bank Stocks Hit Record Highs on Dec 16, 2025: DBS and OCBC Surge, UOB Lags as Investors Eye Dividends and 2026 Momentum

SINGAPORE — December 16, 2025. Singapore’s bank-heavy equity market delivered a fresh headline on Tuesday: DBS and OCBC both notched new all-time highs, reinforcing a late‑2025 narrative that the “big three” banks remain core holdings for income-focused investors—just as the debate shifts to whether the rally can hold into 2026. The Business Times But the story is bigger than a single day’s price action. What’s driving the sector now is a powerful mix of capital return expectations, structural wealth inflows, a loan-growth rebound, and a new China-linked payments milestone for DBS—while UOB’s asset-quality and provisioning profile continues to keep it
16 December 2025
···
1 … 653 654 655 656 657 … 890

Stock Market Today

Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

7 February 2026
Apple closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. The S&P 500 jumped 1.97% and the Nasdaq rose 2.18% as chipmakers rallied, while Amazon fell 5.6% on higher capex guidance. Investors await U.S. jobs data Feb. 11 and CPI Feb. 13. Apple’s next dividend is $0.26 per share, payable Feb. 12.
Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop